- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Spain's Almirall Launches Dermatology Digital Health Initiative
Almirall (Barcelona, Spain) has launched its first call for innovation to start-ups focused on dermatology digital health. The Almirall initiative is part of an accelerator program (the Digital Garden) to strengthen the company’s commitment to digital innovation. The winning five start-ups will be announced on November 14 at the Frontiers Health 2019 event in Berlin, Germany. The winning project teams will begin a nine-month acceleration program in January 2020 at the Barcelona Health Hub headquarters, with the objective of securing venture capital funding. In addition, the start-ups will receive up to €50K in grants, mentoring from pharma industry experts, and the opportunity to leverage leading hospitals in Barcelona as "test beds" for digital pilots. Companies can apply at almiralldigitalgarden.com almirall.com
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
